A groundbreaking personalized mRNA vaccine against pancreatic cancer has demonstrated encouraging results in clinical trials. Patients who mounted an immune response to the vaccine have shown no signs of cancer recurrence after more than three years of follow-up. The vaccine works by stimulating the production of T cells that can potentially last for up to 100 years while maintaining their ability to recognize and combat cancer cells. This innovative approach to cancer treatment leverages the body’s immune system to provide long-term protection against this aggressive form of cancer.
